Helen M. Thackray - Apr 3, 2023 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: Chief R&D Officer
Signature: /s/ Alane P. Barnes, by power of attorney
Stock symbol: BCRX
Transactions as of: Apr 3, 2023
Transactions value $: -$58,030
Form type: 4
Date filed: 4/5/2023, 04:33 PM
Previous filing: Apr 4, 2023
Next filing: Jun 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Sale	-$58K	-7K	-3.27%	$8.29	207K	Apr 3, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 25,000 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
F2	The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.24 to $8.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Content

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 25,000 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.24 to $8.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.